Search results for "PROGRESS"

showing 10 items of 1620 documents

DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB

2020

Abstract DCTN1 encodes the largest subunit of dynactin complex essential in the retrograde axonal transport and cytoplasmic transport of vesicles; mutations in DCTN1 have been reported predominantly in individuals with Perry syndrome and, recently, in patients with progressive supranuclear palsy. Our genetic screening of DCTN1 in 79 patients with progressive supranuclear palsy, 100 patients with multiple system atrophy, and 28 patients with dementia with Lewy bodies from Italy revealed only synonymous and intronic variants, suggesting that DCTN1 mutations do not have a key role in the development of atypical parkinsonism in the Italian population.

Lewy Body DiseaseMale0301 basic medicineAgingPathologymedicine.medical_specialtyDementia with Lewy bodieDNA Mutational AnalysisDynactinProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineAtrophymedicineHumansIn patientGenetic TestingGenetic Association StudiesAgedDCTN1Dementia with Lewy bodiesbusiness.industryProgressive supranuclear palsyGeneral NeuroscienceParkinson DiseaseDynactin ComplexMiddle AgedMultiple System Atrophymedicine.diseaseDCTN1030104 developmental biologyItalyMutation testingDynactinAxoplasmic transportDCTN1; Dementia with Lewy bodies; Dynactin; Multiple system atrophy; Progressive supranuclear palsyFemaleSupranuclear Palsy ProgressiveNeurology (clinical)Geriatrics and GerontologybusinessNegative Results030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.

2008

Objective:  i) to describe the neuropsychiatric profile of elderly subjects with dementia by comparing vascular (VaD) and degenerative dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD); ii) to assess whether the severity and type of dementia are associated with clinically relevant neuropsychiatric symptoms (CR-NPS). Method:  One hundred and thirty-one out-patients with VaD, 100 with DLB and 690 with AD were studied. NPS were evaluated by the neuropsychiatric inventory (NPI). Results:  Vascular dementia had lower total and domain-specific NPI scores and a lower frequency of CR-NPS than AD and DLB, for which frequency of CR-NPS increased significantly with disease s…

Lewy Body DiseaseMalemedicine.medical_specialtyPathologyPsychometricsDiseaseNeuropsychological TestsCentral nervous system diseaseDegenerative diseaseAlzheimer DiseaseInternal medicinemental disordersmedicineDementiaHumansVascular dementiaAgedAged 80 and overLewy bodyDementia with Lewy bodiesDementia Vasculartechnology industry and agricultureReproducibility of Resultsneuropsychiatric symptoms vascular dementia dementia with Lewy bodies Alzheimer’s disease dementia severitymedicine.diseasePsychiatry and Mental healthnervous systemDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer's diseasePsychologyActa psychiatrica Scandinavica
researchProduct

Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial.

2017

AbstractThe study aimed to assess whether aerobic exercise (AEx) training and a fibre-enriched diet can reduce hepatic fat content (HFC) and increase glycaemic control in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD). Six-hundred-and-three patients from seven clinics in Yangpu district, Shanghai, China were recruited. Of them 115 individuals aged 50–65-year fulfilled the inclusion criteria (NAFLD with impaired fasting glucose or impaired glucose tolerance) and were randomly assigned into exercise (AEx n = 29), diet (Diet n = 28), exercise plus diet (AED n = 29), or no-intervention (NI n = 29) groups. Progressive supervised AEx training (60–75% VO2max intensity) was gi…

Lifestyle modificationMaleLIFE-STYLE INTERVENTIONSlcsh:MedicineruokavaliotGastroenterologyImpaired glucose tolerance0302 clinical medicineWeight lossNon-alcoholic Fatty Liver DiseaseMedicinelcsh:Science10. No inequalityIN-VIVOAdipositySPECTROSCOPYMultidisciplinaryINSULIN SENSITIVITYdietary fibreFatty liverrasvamaksaMiddle Aged3. Good healthIntention to Treat AnalysisTreatment OutcomeLiverdietsDisease Progression030211 gastroenterology & hepatologyFemaleaerobic trainingmedicine.symptommedicine.medical_specialtyTYPE-2 DIABETES-MELLITUSWEIGHT-LOSS030209 endocrinology & metabolismArticlePrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEInsulin resistanceInternal medicineAerobic exerciseHumansHEPATIC STEATOSISExercise physiologyExerciseMETAANALYSISfatty liverGlycated HemoglobinIntention-to-treat analysisHepatologybusiness.industrylcsh:Raerobinen harjoittelumedicine.diseaseImpaired fasting glucoseDietravintokuitulcsh:QNORDIC WALKINGInsulin ResistancebusinessBiomarkersScientific reports
researchProduct

Assessing natural metalinguistic skills in people with Alzheimer’s disease and frontotemporal dementia

2019

Abstract Objective The aim of this paper is to assess whether the use of natural metalinguistic skills can be used to differentiate linguistic-communicative profiles of people with dementia (Alzheimer’s disease and frontotemporal dementia in the behavioural and primary progressive aphasia variants) in the earliest stages of the disease. Method A sample of 180 people was selected. Sixty had Alzheimer’s disease, 20 had frontotemporal dementia of the behavioural variant, and 40 had frontotemporal dementia of the primary progressive aphasia variant (20 had non-fluent primary progressive aphasia and 20 had semantic dementia). The control group was composed of 60 healthy people with ages, gender,…

Linguistics and LanguageCognitive NeuroscienceSemantic dementiaLinguisticsExperimental and Cognitive PsychologyDiseaseNeuropsychological TestsLPN and LVNmedicine.diseaseAdditional researchTest (assessment)Primary progressive aphasiaSpeech and HearingAphasia Primary ProgressiveAlzheimer DiseaseFrontotemporal Dementiamental disordersmedicineHumansDementiaInternal validityPsychologyFrontotemporal dementiaClinical psychologyJournal of Communication Disorders
researchProduct

Els mecanismes de referència en la interfície gramàtica-discurs. Cohesió, coherència i cognició

2018

La cohesió referencial integra una sèrie de mecanismes gramaticals lèxics de tipus fòric que estableixen lligams de caràcter sintàctic i semàntic entre les entitats discursives. Mitjançant la referència, els significats textuals s?entreteixeixen, de manera que es creen una sèrie de xarxes correferencials i de sentit a través de les quals s?encadenen els mots per contribuir a la cohesió textual.  Com a fenomen que inclou la pronominalització, l?el·lipsi o anàfora zero, la dixi textual (que es concreta bàsicament en l?ús no exofòric de demostratius) i una varietat de mecanismes de cohesió lèxica (relacions de repetició, reiteració i associació), la cohesió referencial se situa en la interfíci…

Linguistics and LanguageGrammarmedia_common.quotation_subjectCognitionDeixisThematic progressionLanguage and LinguisticsLinguisticsCohesion (linguistics)NounPhenomenonPsychologySentencemedia_common
researchProduct

Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression

2008

Abstract Background Hypoxia-inducible factor 1 alpha (HIF-1α) is involved in processes promoting carcinogenesis of many tumors. However, its role in the development of colorectal cancer is unknown. To investigate the significance of HIF-1α during colorectal carcinogenesis and progression we examined its expression in precursor lesions constituting the conventional and serrated pathways, as well as in non-metastatic and metastatic adenocarcinomas. Methods Immunohistochemistry and Western blot is used to analyse HIF-1α expression in normal colonic mucosa, hyperplastic polyps (HPP), sessile serrated adenomas (SSA), low-grade (TA-LGD) and high-grade (TA-HGD) traditional adenomas as well as in n…

LipopolysaccharidesCancer ResearchPathologymedicine.medical_specialtyColorectal cancerColonic PolypsMouse model of colorectal and intestinal cancermedicine.disease_causelcsh:RC254-282chemistry.chemical_compoundWestern blotCell Line TumorGeneticsMedicineHumansNeoplasm Metastasismedicine.diagnostic_testbusiness.industrymedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunitlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryVascular endothelial growth factorCell Transformation NeoplasticOncologychemistryHyperplastic PolypTumor progressionDisease ProgressionImmunohistochemistrybusinessCarcinogenesisColorectal NeoplasmsPrecancerous ConditionsResearch ArticleBMC Cancer
researchProduct

Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock.

2007

Abstract α−galactosylceramide, a natural killer T cell ligand, and its synthetic homolog, KRN7000, consistently influence IFN-γ and TNF-α release, both mediators of LPS-induced shock. To modify the course of endotoxin shock, we injected KRN7000 at different time points of experimental systemic Shwartzman reaction. Mice treated with KRN7000 survived when it was injected within 2 h before and after LPS challenge. Mice survival was associated with low levels of T helper 1 (Th1) cytokines, such as IFN-γ and TNF-α. By contrast, protection from endotoxin shock was associated with an increase of T helper 2 (Th2) cytokines, like IL-4 and IL-10. A role of Th2 cytokines in counteracting LPS-induced s…

LipopolysaccharidesMaleLipopolysaccharideImmunologyStimulationGalactosylceramidesBiologychemistry.chemical_compoundMiceStructure-Activity RelationshipTh2 CellsIn vivomedicineImmunology and AllergyAnimalsrodent cytokines endotoxinT-cell receptorCell BiologyTh1 CellsLigand (biochemistry)Natural killer T cellShock SepticKiller Cells NaturalMice Inbred C57BLDisease Models AnimalchemistryShock (circulatory)Immunologybiology.proteinDisease ProgressionCytokinesmedicine.symptomAntibodyShwartzman Phenomenon
researchProduct

Effect of Pro-inflammatory Stimuli on Tumor Cell-Mediated Induction of Endothelial Cell Adhesion Molecules in Vitro

2002

The object of our study was the question about the relevance of the tumor surrounding inflammatory cells with respect to the metastatic potential of the tumor cells. To imitate the role of inflammatory cells, three colon carcinoma (HT-29, HRT-18, and SW-620), one breast carcinoma (MCF-7), and one melanoma (ST-ML-12) cell lines were treated with pro-inflammatory stimuli, LPS, TNF-alpha, or IL-1beta. HUVEC monolayers were then stimulated by the collected supernatants (SN) of the tumor cells, following washing out of the applied stimuli. Analysis of CAM expression on HUVEC was performed using cell enzyme immunoassay. E-selectin, VCAM-1, and, in part, ICAM-1 were significantly up-regulated on H…

LipopolysaccharidesPathologymedicine.medical_specialtyEndotheliummedicine.medical_treatmentClinical BiochemistryCellVascular Cell Adhesion Molecule-1Breast NeoplasmsBiologyPathology and Forensic MedicineImmunoenzyme TechniquesNeoplasmsE-selectinTumor Cells CulturedmedicineHumansMelanomaMolecular BiologyCells CulturedInflammationTumor Necrosis Factor-alphaCell adhesion moleculeCarcinomaIntercellular Adhesion Molecule-1Up-Regulationmedicine.anatomical_structureCytokineTumor progressionCell cultureCulture Media ConditionedColonic Neoplasmsbiology.proteinCancer researchFemaleTumor necrosis factor alphaEndothelium VascularE-SelectinCell Adhesion MoleculesInterleukin-1Experimental and Molecular Pathology
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct

Liver fibrosis: Direct antifibrotic agents and targeted therapies

2018

Liver fibrosis and in particular cirrhosis are the major causes of morbidity and mortality of patients with chronic liver disease. Their prevention or reversal have become major endpoints in clinical trials with novel liver specific drugs. Remarkable progress has been made with therapies that efficiently address the cause of the underlying liver disease, as in chronic hepatitis B and C. Highly effective antiviral therapy can prevent progression or even induce reversal in the majority of patients, but such treatment remains elusive for the majority of liver patients with advanced alcoholic or nonalcoholic steatohepatitis, genetic or autoimmune liver diseases. Moreover, drugs that would speed…

Liver Cirrhosis0301 basic medicineCirrhosisDiseaseChronic liver disease03 medical and health sciencesLiver diseaseTransforming Growth Factor betaFibrosisAnimalsHumansMedicineMolecular Targeted TherapyMolecular BiologyExtracellular Matrix ProteinsDDR1business.industrymedicine.disease3. Good healthBiomarker (cell)030104 developmental biologyDisease ProgressionCancer researchHepatic stellate cellbusinessSignal TransductionMatrix Biology
researchProduct